KCNK2 and Alzheimer disease: Previous studies have shown that the blockade (Mazella et al., 2010) or the TREK-1 deletion (Heurteaux et al., 2006) enhances the midbrain 5-HT neuron firing rate, a key parameter predictive of AD efficacy.